# Better Breadth, but Tech Still Has Work to Do

My market notes for 22 October, looking back at the 21 October close: the recovery is encouraging, but I am not treating one green session as an all-clear. These are observations and watchlist plans, not orders or claims that I have taken any of these trades.

The most useful distinction for me is between improving breadth and repaired leadership. RSP holding above its 50-day moving average for a second session is constructive. More participation gives a recovery a better foundation. But QQQ remains below its own 50-day average, so the improvement is not uniform.

That leaves me open to a bounce without assuming a lasting change in trend. A market can offer a tradable rebound and still run into trouble at the next layer of resistance.

Semiconductors are a good example. SMH has a bullish countertrend setup, yet it has not convincingly escaped its recent range. The setup gets my attention; the lack of a clear break keeps me cautious. In the broader technology sector, nearby moving averages and trendline resistance could also make further progress difficult.

My reminder here is simple: support tells me where buyers might appear. It does not tell me how far a bounce will travel. Earnings season adds another uncertainty, because a chart that looks promising at the close can face a very different opening the next morning.

IWM is another useful test. Its recovery has reached the area where the 200-day average and the shorter-term moving average converge. A pause there would be understandable, but a failure is also possible. I want to see what price does next rather than decide in advance that resistance must give way.

On the watchlist, I am separating interesting charts from actionable entries. CRWD has a possible bounce around earlier support. XHB may be building a base, with a squeeze worth monitoring. CRM remains interesting, while WDAY is a reminder that a strong move does not oblige me to chase it.

Biotech also deserves a selective approach. IBB has followed through on its breakout, while XBI has struggled at trendline resistance. A constructive view of a sector is not a reason to treat every instrument within it as interchangeable.

For tonight, my takeaway is patience. I have no fresh option entry to set out in this note. I would rather keep a short watchlist and wait for a clearer trigger than turn every possible bounce into a trade.

Better breadth is welcome. Tech still has work to do. I can acknowledge both without forcing a decision.

*Options involve substantial risk and may not be suitable for every investor.*